

Biotransformation of Anti-cancer Drugs: Role of Cytochrome P450 Enzymes

Amir Farhan*

Department of Biochemistry, American University of Beirut, Lebanon

Received: 02 September 2024; Manuscript No: ijpcbs-24-148816; **Editor assigned:** 04 September 2024; PreQC No: ijpcbs-24-148816 (PQ); **Reviewed:** 18 September 2024; QC No: ijpcbs-24-148816; **Revised:** 23 September 2024; Manuscript No: ijpcbs-23-148816 (R); **Published:** 30 September 2024

INTRODUCTION

Biotransformation is the process by which drugs are chemically altered in the body to enhance their elimination, often through metabolic reactions in the liver. In the case of anti-cancer drugs, biotransformation plays a crucial role in determining both the therapeutic efficacy and toxicity of treatments. A key player in this process is the Cytochrome P450 (CYP) enzyme family, which is responsible for the metabolism of many xenobiotics, including chemotherapeutic agents. These enzymes catalyze oxidative reactions that convert lipophilic drugs into more water-soluble metabolites, facilitating their excretion. Understanding the role of CYP enzymes in the biotransformation of anti-cancer drugs is essential for optimizing cancer therapy, minimizing adverse effects, and avoiding drug interactions. For instance, CYP3A4, one of the most abundant enzymes in the liver, is responsible for the metabolism of many chemotherapeutic drugs such as cyclophosphamide, tamoxifen, and docetaxel [1,2]. The activity of CYP3A4 and other CYP enzymes can influence both the activation of prodrugs and the detoxification of active agents. Without this enzymatic conversion, the drug would remain inactive and ineffective against the tumor. However, CYP-mediated metabolism is a double-edged sword, as it can also lead to the generation of toxic byproducts or reduce the efficacy of anti-cancer drugs by increasing their clearance from the body. For instance, excessive metabolism of certain drugs can result in sub therapeutic concentrations, reducing their ability to kill cancer cells [1,2].

DESCRIPTION

This genetic variability in CYP enzyme activity highlights the importance of pharmacogenomics in personalizing anti-cancer treatment. Drug-Drug Interactions (DDIs) are another significant concern in the biotransformation of anti-cancer

drugs, especially when multiple medications are prescribed concurrently. Many chemotherapeutic agents are substrates, inhibitors, or inducers of CYP enzymes, which means they can either compete for metabolism or alter the expression of these enzymes. For example, paclitaxel, a commonly used chemotherapeutic agent, is metabolized by CYP2C8 and CYP3A4. When used in combination with drugs that inhibit these enzymes, such as antifungal agents or certain antibiotics, the metabolism of paclitaxel can be impaired, leading to increased toxicity. On the other hand, drugs that induce CYP enzymes, such as rifampicin, can enhance the metabolism of anti-cancer drugs, reducing their plasma concentration and therapeutic efficacy. The complexity of CYP enzyme-mediated biotransformation is further compounded by factors such as age, gender, liver function, and environmental influences. For instance, elderly patients may have reduced CYP enzyme activity, leading to slower drug metabolism and an increased risk of toxicity. Additionally, conditions such as liver cirrhosis or hepatitis, which are common in cancer patients due to either the disease itself or concomitant medications, can impair the function of CYP enzymes, further complicating drug metabolism and dosing strategies [3,4].

CONCLUSION

In conclusion, the cytochrome P450 enzymes play a critical role in the biotransformation of anti-cancer drugs, influencing their activation, detoxification, and elimination. By understanding the interactions between these enzymes and chemotherapeutic agents, clinicians can better predict drug response, minimize toxicity, and optimize treatment outcomes. The field of pharmacogenomics offers great potential in tailoring cancer therapies to individual patients based on their CYP enzyme activity, ultimately improving the precision and effectiveness of cancer treatment.

ACKNOWLEDGMENT

None.

CONFLICT OF INTEREST

None.

REFERENCES

1. Netea MG, Dominguez-Andres J, Barreiro LB, Chavakis T, Divangahi M, et al. Defining trained immunity and its role in health and disease. *Nat Rev Immunol* 2020; 20(6):375-388.
2. Ebihara T. Dichotomous regulation of acquired immunity by innate lymphoid cells. *Cells* 2020; 9(5):1193.
3. Sun L, Wang X, Saredy J, Yuan Z, Yang X, et al. Innate-adaptive immunity interplay and redox regulation in immune response. *Redox Biol* 2020; 37:101759.
4. Carpenter S, Neill LAJ. From periphery to center stage: 50 years of advancements in innate immunity. *Cell* 2024; 187(9):2030-2051.